Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: A retrospective cohort study

Pediatric Critical Care Medicine

Volumn 15, Issue 8, 2014, Pages e340-e346

  Ryerson, Lindsay M ^a   Bauman, Mary E ^a   Kuhle, Stefan ^b   Bruce, Aisha A ^a   Massicotte, M Patricia ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

Author keywords

Anti factor xa activity; Anticoagulation; Antithrombin; Children; Heparin; Infants

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A; HEPARIN; RECOMBINANT ANTITHROMBIN III; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR;

ANAPHYLACTIC SHOCK; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CHILD; CHILD CARE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EXTRACORPOREAL OXYGENATION; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT INDICATION; URTICARIA; VENTRICULAR ASSIST DEVICE; BLOOD; BODY WEIGHT; NEWBORN; PRESCHOOL CHILD;

ANTICOAGULANTS; ANTITHROMBINS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; FACTOR XA INHIBITORS; FEMALE; HEPARIN; HUMANS; INFANT; INFANT, NEWBORN; MALE; PARTIAL THROMBOPLASTIN TIME; RETROSPECTIVE STUDIES;

EID: 84918803628     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0000000000000174     Document Type: Article

References (36)

1. Raffini L, Huang YS, Witmer C, et al: Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124:1000-1008.
2. Andrew M: Indications and drugs for anticoagulation therapy in children. Thromb Res 1996; 81:S61-S73.
3. Monagle P, Chan AK, Goldenberg NA, et al; American College of Chest Physicians: Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e737S-e801S.
4. Newall F, Johnston L, Monagle P, et al: Unfractionated heparin therapy in infants and children. Pediatrics 2009; 123:510-518.
5. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant. Blood 1987; 70:165-172.
6. Monagle P, Massicotte P: Developmental haemostasis: Secondary haemostasis. Semin Fetal Neonatal Med 2011; 16:294-300.
7. Andrew M, Brooker L, Mitchell L: Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 1994; 5(Suppl 1):S24-S36; discussion S59-64.
8. Andrew M, Massicotte-Nolan P, Mitchell L, et al: Dysfunctional antithrombin III in sick premature infants. Pediatr Res 1985; 19:237-239.
9. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and lowmolecular- weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119:64S-94S.
10. Levine MN, Hirsh J, Gent M, et al: A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154:49-56.
11. Giglia TM, Massicotte MP, Tweddell JS, et al; American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Stroke Council: Prevention and treatment of thrombosis in pediatric and congenital heart disease: A scientific statement from the American Heart Association. Circulation 2013; 128:2622-2703.
12. Baxter: Antithrombin III Immuno (Antithrombin III (Human), E.P). Vienna, Austria, Baxter, 2010.
13. Mitchell LG, Goldenberg NA, Male C, et al; Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH: Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 2011; 9:1856-1858.
14. Andrew M, Marzinotto V, Massicotte P, et al: Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 1994; 35:78-83.
15. Hoffman EB, Sen PK, Weinberg CR: Within-cluster resampling. Biometrika 2001; 88:1121-1134.
16. Young E, Prins M, Levine MN, et al: Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67:639-643.
17. Baker BA, Adelman MD, Smith PA, et al: Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997; 157:2475-2479.
18. Kuhle S, Eulmesekian P, Kavanagh B, et al: Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92:554-557.
19. Chan AK, Leaker M, Burrows FA, et al: Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997; 77:270-277.
20. Hirsh J, Bauer KA, Donati MB, et al; American College of Chest Physicians: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S-159S.
21. Newall F, Ignjatovic V, Johnston L, et al: Clinical use of unfractionated heparin therapy in children: Time for change? Br J Haematol 2010; 150:674-678.
22. Herbert JM, Hérault JP, Bernat A, et al: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 1998; 91:4197-4205.
23. Andersson LO, Barrowcliffe TW, Holmer E, et al: Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res 1976; 9:575-583.
24. Sobel M, Fish WR, Toma N, et al: Heparin modulates integrin function in human platelets. J Vasc Surg 2001; 33:587-594.
25. Yagi M, Murray J, Strand K, et al: Heparin modulates the conformation and signaling of platelet integrin alphaIIbbeta3. Thromb Res 2012; 129:743-749.
26. Xiao Z, Théroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecularweight heparin and with a direct thrombin inhibitor. Circulation 1998; 97:251-256.
27. Aggarwal A, Whitaker DA, Rimmer JM, et al: Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant 2004; 19:1559-1563.
28. Rauova L, Zhai L, Kowalska MA, et al: Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 2006; 107:2346-2353.
29. Kozul C, Newall F, Monagle P, et al: A clinical audit of antithrombin concentrate use in a tertiary paediatric centre. J Paediatr Child Health 2012; 48:681-684.
30. Urlesberger B, Zobel G, Zenz W, et al: Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 1996; 129:264-268.
31. Agati S, Ciccarello G, Salvo D, et al: Use of a novel anticoagulation strategy during ECMO in a pediatric population: Single-center experience. ASAIO J 2006; 52:513-516.
32. Niebler RA, Christensen M, Berens R, et al: Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 2011; 35:1024-1028.
33. Schmidt B, Gillie P, Mitchell L, et al: A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158:470-476.
34. O'Reilly MS: Antiangiogenic antithrombin. Semin Thromb Hemost 2007; 33:660-666.
35. Salvatierra A, Guerrero R, Rodriguez M, et al: Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog. Circulation 2001; 104:2975-2980.
36. Jormalainen M, Vento AE, Wartiovaara-Kautto U, et al: Antithrombin reduces pulmonary hypertension during reperfusion after cardiopulmonary bypass in a pig. Acta Anaesthesiol Scand 2007; 51: 178-188.